Brief: Acucort Reports Positive Results From First Of Two Bioequivalence Studies For US
18/03/2019 09:56
March 18 (Reuters) - AcuCort AB ACUC.TE :
* REPORTS POSITIVE RESULTS FROM FIRST OF TWO BIOEQUIVALENCE
STUDIES FOR US
* RESULTS SHOW THAT CO'S DRUG CANDIDATE DEXA ODF IS
BIOEQUIVALENT
TO COMPARISON REFERENCE PRODUCT
Source text for Eikon: ID:nWkr7Qm2QV
Further company coverage: ACUC.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA